Hofseth BioCare ASA
Hofseth BioCare ASA
04/08/2022 | Press release | Distributed by Public on 04/08/2022 07:53
Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2022
Tid08.04.2022, 13:49:25
MeldingsID559057
UtstederIDHBC
MarkedOslo Børs
Andre språk
Korrigerte versjoner
KategoriANNEN INFORMASJONSPLIKTIG REGULATORISK INFORMASJON
-
Informasjonspliktige opplysningerInformasjonspliktige opplysninger i henhold til lov, forskrift eller børsens egne regler for markedet verdipapiret er notert på.
-
Lagringspliktig meldingMed lagringspliktige meldinger menes meldinger som skal oppbevares i offisiell lagringsmekanisme (OAM) etter verdipapirhandelloven § 5-12 og/eller børsens egne regler.
Del melding
Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2022
The Annual General Meeting of Hofseth BioCare ASA will be held at the company's
premises at Kipervikgata 13, 6003 Ålesund, on 29 April 2022 at 13:00 CET.
Please find the notice to the Annual General Meeting attached and relevant
documents referred to in the notice are made available on
www.hofsethbiocare.com.
For further information, please contact:
Jon Olav Ødegård, CFO of Hofseth BioCare ASA
Phone: +47 93632966
E-mail: [email protected] (mailto:[email protected])
About Hofseth BioCare ASA
HBC is a Norwegian consumer and pet health ingredient supplier and an incubator
for new drug leads. Research is ongoing to identify the individual elements
within its ingredients that modulate inflammation and the immune response with
pre-clinical studies in multiple clinics and university research labs in several
countries. Lead clinical and pre-clinical candidates are focused on developing
an oral pharmaceutical lead program to treat inflammatory disease driven by
eosinophils. Preclinical trial work with the oil is ongoing to ameliorate lung
inflammation in eosinophilic asthma and COPD ("smokers lung") as well as
clinical work in COVID. Other leads are focused on the protection of the Gastro-
Intestinal (GI) system against inflammation (including ulcerative colitis and
the orphan condition necrotising enterocolitis) and using peptide fractions of
salmon protein hydrolysate (SPH also known as 'ProGo') as a Medical Food to help
treat age-related Sarcopenia, and as a treatment for Iron Deficiency Anemia.
The company is founded on the core values of sustainability, optimal utilization
of natural resources and full traceability. Through an innovative hydrolysis
technology, HBC can preserve the quality of lipids, proteins and calcium from
fresh salmon off-cuts.
Hofseth BioCare's headquarters are in Ålesund, Norway with branches in Oslo,
London, Zürich, New Jersey, and Palo Alto.
This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act
premises at Kipervikgata 13, 6003 Ålesund, on 29 April 2022 at 13:00 CET.
Please find the notice to the Annual General Meeting attached and relevant
documents referred to in the notice are made available on
www.hofsethbiocare.com.
For further information, please contact:
Jon Olav Ødegård, CFO of Hofseth BioCare ASA
Phone: +47 93632966
E-mail: [email protected] (mailto:[email protected])
About Hofseth BioCare ASA
HBC is a Norwegian consumer and pet health ingredient supplier and an incubator
for new drug leads. Research is ongoing to identify the individual elements
within its ingredients that modulate inflammation and the immune response with
pre-clinical studies in multiple clinics and university research labs in several
countries. Lead clinical and pre-clinical candidates are focused on developing
an oral pharmaceutical lead program to treat inflammatory disease driven by
eosinophils. Preclinical trial work with the oil is ongoing to ameliorate lung
inflammation in eosinophilic asthma and COPD ("smokers lung") as well as
clinical work in COVID. Other leads are focused on the protection of the Gastro-
Intestinal (GI) system against inflammation (including ulcerative colitis and
the orphan condition necrotising enterocolitis) and using peptide fractions of
salmon protein hydrolysate (SPH also known as 'ProGo') as a Medical Food to help
treat age-related Sarcopenia, and as a treatment for Iron Deficiency Anemia.
The company is founded on the core values of sustainability, optimal utilization
of natural resources and full traceability. Through an innovative hydrolysis
technology, HBC can preserve the quality of lipids, proteins and calcium from
fresh salmon off-cuts.
Hofseth BioCare's headquarters are in Ålesund, Norway with branches in Oslo,
London, Zürich, New Jersey, and Palo Alto.
This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act